Moderna’s two-dose COVID-19 vaccine was 44% effective at preventing infection from Omicron in children 6 months to under 2 years old and roughly 38% effective for children ages 2 to 5 years, according to data released by the company on Wednesday (March 23).
None of the children in the trial developed severe illness from COVID-19 and the majority of breakthrough cases were mild, according to the biotech company.
Moderna will ask the FDA to grant emergency use authorization for the vaccine for children under 6 years old as soon as possible, CEO Stephane Bancel said in a statement.